The effect of simvastatin on serum cytokine levels and bone metabolism in postmenopausal subjects: Negative correlation between TNF-α, and anabolic bone parameters

Journal of Bone and Mineral Metabolism

Volumn 22, Issue 4, 2004, Pages 365-371

  Tikiz, Canan ^a   Ünlü, Zeliha ^a   Tikiz, Hakan ^a   Ay, Kamuran ^a   Angin, Aclan ^a   Onur, Ece ^a   Var, Ahmet ^a   Tüzün, Çiǧdem ^a  

^a CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

Bone turnover; Cytokine; IL 6; Osteoporosis; Simvastatin; TNF

Indexed keywords

BIOCHEMICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; CYTOKINE; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BONE METABOLISM; BONE TURNOVER; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; OSTEOCLAST; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK BENEFIT ANALYSIS;

EID: 3242742283     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-004-0496-0     Document Type: Article

References (43)

1. Takemoto M, Liao JK (2001) Pleiotropic effects of 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21:1712-1719
2. Bauer DC (2003) HMG CoA reductase inhibitors and the skeleton: a comprehensive review. Osteoporos Int 14:273-282
3. Massy ZA, Keane WF, Kasiske BL (1996) Inhibition of the mevalonate pathway, benefits beyond cholesterol reduction. Lancet 347:102-103
4. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946-1949
5. Bauer D, Mundy G, Jamal SA, Black DM, Cauley JA, Ensrud KE, van der Klift M, Pols HA (2004) Use of statins and frature: results of four prospective studies and comulative meta-analysis of observational studies and controlled trials. Arch Intern Med 26:146-152
6. Edwards CJ, Hart DJ, Spector TD (2000) Oral statins and increased bone mineral density in postmenopausal women. Lancet 355:2218-2219
7. Wada Y, Nakamura Y, Koshiyama H (2000) Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes. Arch Intern Med 160:2865
8. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM (1995) Risk factors for hip fracture in white women. N Engl J Med 332:767-773
9. Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR (1993) Design of the Fracture Intervention Trial. Osteoporos Int 3 (Suppl 3):S29-S39
10. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280:605-613
11. Chan MH, Mak TW, Chiu RW, Chow C, Chan IH, Lam CW (2001) Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolemia. J Clin Endocrinol Metab 86:4556-4559
12. Stein EA, Farnier M, Waldstreicher J, Mercuri M (2001) Effects of statins on biomarkers of bone metabolism: a randomized trial. Nutr Metab Cardiovasc Dis 11:84-87
13. Mostaza JM, De la Piedra C, Curiel MD, Pena R, Lahoz C (2001) Pravastatin therapy increases procollagen I N-terminal propeptide. Clin Chim Acta 308:133-137
14. Bjarnason NH, Riis BJ, Christiansen C (2001) The effect of fluvastatin on parameters of bone remodeling. Osteoporos Int 12:380-384
15. Pacifici R, Avioli LV (1993) The effects of natural and surgical menopause on the secretion of cytokines from human blood monocytes. Osteoporos Int 381:106-107
16. Horowitz MC (1993) Cytokines and estrogen bone: anti-osteoporotic effects. Science 260:626-627
17. Schieffer B, Drexler H (2003) Role of HMG-CoA reductase inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular disease. Am J Cardiol 91:12H-18H.
18. Nussbaum S, Potts JT (1994) Advances in immunoassays for parathyroid hormone. Clinical applications to skeletal disorders of bone and mineral metabolism. In: Bilezikian JP, Levine MA, Marcus R (eds) The Parathyroids: Basics and Clinical Concepts. Raven, New York, pp 157-169
19. World Health Organization (1994) Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. WHO technical report series 843, Geneva
20. Maeda T, Matsunuma A, Kawane T, Horiuchi N (2000) Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 280:874-877
21. Bauer DC, Mundy G, Jamal S (1999). Statin use, bone mass and fracture: an analysis of two prospective studies. J Bone Miner Res (Suppl):1188
22. Cummings S, Bauer DC (2000) Do statins prevent both cardiovascular disease and fracture? JAMA 283:3255-3257
23. Wang PS, Solomon DH, Mogun H, Avorn J (2000) HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283:3211-3216
24. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R (2000) Inhibitors of hydroxymethylglutaryl- coenzyme A reductase and risk of fracture among older women. Lancet 355:2185-2188
25. Pasco J, Kotowicz M, Henry M, Sanders K, Nicholson G (2002) Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 162:537-540
26. Barengolts E, Karanouth D, Kolodny L, Kukreja S (2001) Risk factors for hip fracture in predominantly African-American veteran male population. J Bone Miner Res 16 (Suppl):S170
27. Sirola J, Honkanen R, Kroger H, Jurvelin JS, Maenpaa P, Saarikoski S (2002) Relation of statin use and bone loss: a prospective population-based cohort study in early postmenopausal women. Osteoporos Int 13:537-554
28. Cauley J, Jackson R, Pettinger M (2000) Statin use and bone mineral density (BMD) in older women: The Women's Health Initiative Observational Study (WHI-OS) J Bone Miner Res 15 (Suppl 1):1068
29. Chapurlat RD, Cummings SR (2002) Does follow-up of osteoporotic women treated with anti-resorptive therapies improve effectiveness? Osteoporos Int 13:738-744
30. Watanabe S, Fukumoto S, Takeuchi Y, Fujita H, Nakano T, Fujita T (2001) Effects of 1-year treatment with fluvastatin or pravastatin on bone. Am J Med 110:584-587
31. Stein GS, Lian JB (1993) Molecular mechanism mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. Endocr Rev 14:424-444
32. Rejnmark L, Buus NH, Vestergaard P, Andreasen F, Larsen ML, Mosekilde L (2002) Statins decrease bone turnover in postmenopausal women: a cross-sectional study. Eur J Clin Invest 32:581-589
33. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S (2000) Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 271:688-692
34. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S, Sharpe N (2001) Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomized controlled trial. Lancet 357:509-512
35. Manolagas SC, Jilka RL (1995) Bone marrow, cytokine and bone remodeling. N Engl J Med 332:305-311
36. Pacific R (1996) Estrogen, cytokine, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 11:1043-1051
37. Salamone LM, Whiteside T, Friberg D, Epstein RS, Kuller LH, Cauley JA (1998) Cytokine production and bone mineral density at the lumbar spine and femoral neck in premenopausal women. Calcif Tissue Int 63: 466-470
38. Grip O, Janciauskiene S, Lindgren S (2002) Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. Inflamm Res 51:58-62
39. Inoue I, Goto S, Mizotani K, Awata T. Mastunaga T, Kawai S, Nakajima T, Hokari S, Komoda T, Katayama S (2000) Lipophilic MHG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for IL1beta, IL-6, COX-2 and p22phox by regulation of peroxisome proliferator activated receptor alpha in primary endothelial cells. Life Sci 67:863-876
40. Pietschmann P, Grisar J, Thien R, Willheim M, Kerschan-Schindl K, Preisinger E, Peterlik M (2001) Immune phenotype and intracellular cytokine production of peripheral blood mononuclear cells from postmenopausal patients with osteoporotic fractures. Exp Gerontol 36:1749-1759
41. Weis M, Pehlivanli S, Meiser BM, von Scheldt W (2001) Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation after heart transplantation. J Am Coll Cardiol 38:814-818
42. Rezaie-Majd A, Prager GW, Bucek RA, Schernthaner GH, Maca T, Kress HG, Valent P, Binder BR, Minar E, Baghestanian M (2003) Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 23:397-403
43. Whiteside TL (1994) Cytokines and interpretation of assays in human disease. J Clin Immunol 14: 327-339